Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Union Pacific Corporation — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Union Pacific Corporation trades at $287 (market cap $167.74B). The key difference: Union Pacific Corporation is far larger — about 34.4× Travere Therapeutics Inc. Common Stock's market cap, and Union Pacific Corporation pays a 2.01% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Union Pacific Corporation for 105 Days on average.
| TVTX | UNP | |
|---|---|---|
Market Cap | $4.88B | $167.74B |
Volume | 1,668,577 | 1,359,371 |
Sector | Health | Industrials |
52-Week High | $67.52 | $310.62 |
52-Week Low | $26.79 | $216.37 |
Typical Hold Time | 0 Days | 105 Days |
Enterprise Value | $5.01B | $196.80B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Union Pacific (UNP) trades at $286.43, up 1.73% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 28.85% net income margin and 39.7% ROE, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by analyst upgrades, a consensus buy rating, and a $332.10 price target, alongside developments in battery-electric locomotives and the pending Norfolk Southern combination.
The outlook for UNP is favorable, with earnings growth and dividend stability offering investment appeal. Risks include merger uncertainty, fuel cost pressures, and economic cyclicality, but the company's pricing power and infrastructure advantages provide a solid foundation for long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
